Skip to main content
NewslettersWatchlist

Insmed Inc(INSM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low25.31
Day High26.82
Open:26.57
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
The Globe and Mail
14 top U.S. equities to watch for price trend chasers
PR Newswire
Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Motley Fool
Why Shares of Insmed Are Soaring This Week
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Motley Fool
Why Insmed Stock Is Soaring Today
BayStreet.ca
The Five Biotech Stocks Every Investor Should Know About
BayStreet.ca
A Potentially Revolutionary Tuberculosis Test Can Produce Results in 24 Hours
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update
PR Newswire
Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference
PR Newswire
Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference
PR Newswire
Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Insmed Reports First Quarter 2023 Financial Results and Provides Business Update
PR Newswire
Insmed to Host Investor and Analyst Event on May 8, 2023
PR Newswire
Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
PR Newswire
Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Business Wire
Analysts and Executives Converge February 2nd at the 30th Annual Emerald Groundhog Day Investment Forum
PR Newswire
Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference
PR Newswire
Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Insmed To Present at the Nasdaq 47th Investor Conference
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Insmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List
PR Newswire
Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update

Profile

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.